X

Trial Profile

A Phase III Clinical Trial to Evaluate Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifamycin (Primary)
Indications Irritable bowel syndrome
Focus Registrational; Therapeutic Use
Sponsors Cosmo Pharmaceuticals

Most Recent Events

21 Jan 2021 New trial record
11 Jan 2021 According to a Cosmo Pharmaceuticals media release, the company together with its licensees, will immediately commence discussions with the US and EU regulatory agencies with a view to starting the Phase III clinical studies required for marketing authorisation as soon as possible.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com